08.01.2013 • NewsInnospecTPCMergers & Acquisitions (M&A)

Innospec Aims for Sub-$300 Million Acquisition by March End

Fuel additives maker Innospec is looking to buy an oilfield specialty company for less than $300 million by the end of the first quarter, its top executive said.

"We are combing all regions to look at small companies that are under $300 million, some public but mostly privately owned," Chief Executive Patrick Williams told Reuters in an interview.

Innospec withdrew its $745 million offer for TPC Group in early December, paving the way for the acquisition of the chemicals maker by private equity firms First Reserve Corp and SK Capital Partners.

Innospec shares have risen about 13% since it dropped the bid that was backed by Blackstone Group.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.